Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1997-09-15
2001-08-14
Chan, Christina Y. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S328000, C424S278100
Reexamination Certificate
active
06274145
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to an antigen associated with cancer, and the nucleic acid molecule encoding it, as well as the uses of these.
BACKGROUND AND PRIOR ART
It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as “markers” for a particular pathological or abnormal condition. Apart from their use as diagnostic “targets”, i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.
Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.
To date, two strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2275 (1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines which are tested for the expression of the specific antigen. The biochemical approach, exemplified by, e.g., Kawakami, et al., Nature 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromography (HPLC). Antigenic peptides are identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytotoxic T-lymphocytes. These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a
51
Cr release assay.
These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; and second, they depend on the establishment of cytotoxic T cell lines (CTLs) with predefined specificity.
The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der Bruggen et al., Science 254: 1643-1647 (1991); Brichard et al., J. Exp. Med. 178: 489-495 (1993); Coulie, et al., J. Exp. Med. 180: 35-42 (1994); Kawakami, et al., Proc. Natl. Acad. Sci. USA 91: 3515-3519 (1994).
Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., Immunol. Allerg. Clin. North. Am. 10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.
One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. patent applications Ser. No. 08/580,980 now U.S. Pat. No. 5,698,396, and application Ser. No. 08/479,328, filed on Jun. 7, 1995 and Jan. 3, 1996, respectively. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immnoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method (“Serological identification of antigens by Recombinant Expression Cloning”). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340 (1995).
The SEREX methodology has been applied to esophageal cancer samples, and an antigen has now been identified, and its encoding nucleic acid molecule isolated and cloned. The antigen has been found to have more widespread distribution cancer, but had not been found in non-cancerous cells. This, inter alia, is the subject of the invention, which is described in more detail in the disclosure which follows.
REFERENCES:
patent: 4772547 (1988-09-01), Heimer et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5212085 (1993-05-01), Wands et al.
patent: 5811519 (1998-09-01), Lethe et al.
patent: WO 95/25122 (1995-09-01), None
patent: WO9918206 (1999-04-01), None
Chen et al., “A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening”, Proc. Natl. Acad. Sci. USA 94: 1914-1918 (3/97).
Kiyokawa et al., “Overexpression of ERK, an EPH Family Receptor Protein Tyrosine Kinase, in Varous Human Tumors1”, Canc. Res. 54: 3645-3650 (Jul. 15, 1994).
Fazioli et al., “The ezrin-like family of tyrosine kinase substrates: receptor specific pattern of tyrosine phosphorylation and relationship to malignant transformation”, Oncogene 8 (5): 1335-1345 (5/93).
Cruse et a. Illustrated Dictionary of Immunology. CRC Press New York, 1995 p. 83.*
Rammensee et al. Immunogenetics 41: 278, 1992.
Alexander Knuth
Chen Yao-tseng
Drijfhout Jan W.
Gure Ali
Jager Elke
Chan Christina Y.
DiBrino Marianne
Fulbright & Jaworski LLP
Ludwig Institute for Cancer Research
LandOfFree
Isolated nucleic acid molecule encoding cancer associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated nucleic acid molecule encoding cancer associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated nucleic acid molecule encoding cancer associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2514412